- Home
- DCI vs LEGN Comparison
DCI vs LEGN Comparison
Compare DCI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCI | LEGN |
|---|---|---|
| Founded | 1915 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 5.9B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DCI | LEGN |
|---|---|---|
| Price | $85.39 | $36.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $99.00 | $61.33 |
| AVG Volume (30 Days) | 739.7K | ★ 2.7M |
| Earning Date | 06-02-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $2,844,900,000.00 | N/A |
| Revenue This Year | $4.58 | $42.68 |
| Revenue Next Year | $5.18 | $30.52 |
| P/E Ratio | $30.39 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $67.71 | $16.24 |
| 52 Week High | $112.84 | $45.30 |
Technical Indicators
Market Signals| Indicator | DCI | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 65.00 |
| Support Level | $83.13 | $31.84 |
| Resistance Level | $88.43 | $37.50 |
| Average True Range (ATR) | 2.14 | 2.85 |
| MACD | 0.33 | 0.32 |
| Stochastic Oscillator | 69.45 | 86.09 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.